Meeting
2017 Gastrointestinal Cancers Symposium
Role of cetuximab in conversion therapy in advanced KRAS WT colorectal cancer with liver limited disease: A systematic review and meta-analysis.
Authors
Michelle McMullen
Fiona Stanley Hospital, Perth, Australia
Michelle McMullen , Andrew Davidson , Muhammad Adnan Khattak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 748)
DOI
10.1200/JCO.2017.35.4_suppl.748
Abstract #
748
Poster Bd #
L14
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer.
First Author: Yijiao Chen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Preoperative chemotherapy prior to primary tumor resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: A multicenter randomized controlled trial.
First Author: Qi Lin
Poster
2014 ASCO Annual Meeting
An updated systematic review and meta-analysis of randomized controlled trials on duration of chemotherapy for advanced non-small cell lung cancer.
First Author: Yu Yang Soon
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Benefit of immune checkpoint inhibitors (ICI) for patients with advanced esophageal squamous cell carcinoma and low PD-L1 expression: A systematic review and meta-analysis.
First Author: Mario Machado Lopes